Mihaela Biscoveanu, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1033159231
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 34.7% of the total. Reporting peaked in 2019 at $2,820 and has fallen 89.4% since, to $299 in 2025.
Across 72 payments — averaging $53.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- Novo Nordisk AS$1K
- Medtronic$400
- Novo Nordisk$244
- Boehringer Ingelheim$152
- Lilly USA, LLC$115
- plus $377 from 9 others
Across 816 payments — averaging $1950.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$542K
- Boehringer Ingelheim Pharma GmbH & Co.kg$375K
- Boehringer Ingelheim International GmbH$302K
- AbbVie$269K
- Novo Nordisk AS$89K
- Janssen Research & Development, LLC$11K
- plus $4K from 1 others
What the payments were for
- Travel & lodging$1,99252%
- Food & beverage$1,81648%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 6 | $1,323 |
| Novo Nordisk AS | 4 | $1,208 |
| Medtronic(2 entities) | 14 | $400 |
| Novo Nordisk | 16 | $244 |
| Boehringer Ingelheim | 3 | $152 |
| Lilly USA, LLC | 8 | $115 |
| AbbVie | 5 | $69 |
| Johnson & Johnson(2 entities) | 3 | $62 |
| Dexcom, Inc. | 3 | $58 |
| Radius Health, Inc. | 2 | $45 |
| Abbott | 2 | $38 |
| Tandem Diabetes Care, Inc. | 3 | $33 |
| Ascensia Diabetes Care US Inc. | 1 | $29 |
| Mannkind Corporation | 1 | $22 |
| Vistapharm, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$1,306
- MINIMED 780G$103
How this compares
$3,819 in reported general payments places this provider in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 240 | $377,821 |
| JardianceEmpagliflozin | 165 | $195,807 |
| TrulicityDulaglutide | 106 | $124,903 |
| MounjaroTirzepatide | 65 | $114,362 |
| JanumetSitagliptin Phos/Metformin Hcl | 70 | $69,284 |
| JanuviaSitagliptin Phosphate | 66 | $66,792 |
| FarxigaDapagliflozin Propanediol | 72 | $62,496 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $53,893 |
| Tresiba Flextouch U-200Insulin Degludec | 36 | $46,392 |
| ProliaDenosumab | 25 | $42,440 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $38,447 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 221 | $33,959 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $31,377 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $28,313 |
| RybelsusSemaglutide | 11 | $28,302 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $244 | $410,949268 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $115 | $244,506187 claims |
| Boehringer IngelheimJardiance, Tradjenta | $152 | $211,049185 claims |
| AbbVieSynthroid | $69 | $13,745174 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Philadelphia
- Serge JabbourPhiladelphia$1.2M
- Jane MayrinPhiladelphia$628K
- Intekhab AhmedPhiladelphia$528K
- Mitchell LazarPhiladelphia$358K
- Michael RickelsPhiladelphia$65K
- Amna KhanPhiladelphia$39K
- Janna PraterPhiladelphia$22K
- Anne CappolaPhiladelphia$17K
- Anastassia AmaroPhiladelphia$16K
- Monika ShirodkarPhiladelphia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.